Wall Street Zen Upgrades Compass Pathways (NASDAQ:CMPS) to “Sell”

Compass Pathways (NASDAQ:CMPS) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Sunday.

CMPS has been the topic of a number of other research reports. B. Riley Financial raised their price objective on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. UBS Group set a $18.00 target price on shares of Compass Pathways in a report on Thursday, May 7th. Wolfe Research reaffirmed an “outperform” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Maxim Group increased their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Finally, Stifel Nicolaus lifted their price target on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.36.

Compass Pathways Trading Up 2.0%

NASDAQ:CMPS opened at $13.72 on Friday. Compass Pathways has a 1 year low of $3.97 and a 1 year high of $15.40. The stock has a market cap of $1.90 billion, a P/E ratio of -2.97 and a beta of 2.50. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The stock has a 50-day simple moving average of $12.67 and a 200-day simple moving average of $9.63.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Institutional Trading of Compass Pathways

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPS. Ancora Advisors LLC purchased a new stake in shares of Compass Pathways during the second quarter worth approximately $43,000. EverSource Wealth Advisors LLC increased its stake in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after buying an additional 1,920 shares during the period. Persistent Asset Partners Ltd purchased a new position in Compass Pathways during the 4th quarter worth $38,000. Caitong International Asset Management Co. Ltd purchased a new position in Compass Pathways during the 4th quarter worth $47,000. Finally, Advisory Services Network LLC acquired a new stake in shares of Compass Pathways in the 3rd quarter worth $41,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.